Hypertensive nephropathy screening

Hypertensive nephropathy Microchapters
Home
Patient Information
Overview
Classification
Pathophysiology
Differentiating Hypertensive Nephropathy from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Abdominal X Ray
CT
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Hypertensive nephropathy screening On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Hypertensive nephropathy screening All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Hypertensive nephropathy screening
CDC on Hypertensive nephropathy screening
Hypertensive nephropathy screening in the news
Blogs on Hypertensive nephropathy screening
Directions to Hospitals Treating Hypertensive nephropathy
Risk calculators and risk factors for Hypertensive nephropathy screening

Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aarti Narayan, M.B.B.S [2]

Screening

• Microalbuminuria (less than 300 mg/ dl) is the first sign of renal damage secondary to hypertension.
• It is widely used as a screening technique to detect renal damage at an early stage.